Clinical Report: Comparative Analysis of Vaccination Delivery Models in Older Adults

Overview

This report evaluates two models for delivering influenza, COVID-19, and pneumococcal vaccines to hospitalized older adults. The study highlights the effectiveness of a dedicated vaccine prescriber model compared to a medical officer-led approach in increasing vaccination uptake.

Background

Vaccination coverage among older adults is critical due to their heightened risk of severe infections and complications from diseases like influenza, COVID-19, and pneumococcal disease. Despite public health initiatives, vaccination uptake remains low in this demographic, necessitating innovative delivery models to improve access and compliance. Hospital admissions present a unique opportunity to vaccinate high-risk patients who may not engage with primary care services.

Data Highlights

No numerical data provided in the article.

Key Findings

• Older adults are at significant risk for severe outcomes from respiratory infections.
• Only 61.1% of adults aged ≥ 65 years received an influenza vaccine in Australia as of 2024.
• Low uptake of SARS-CoV-2 booster doses was reported, with only 20.6% in adults ≥ 75 years.
• Two models of vaccination delivery were evaluated: medical officer-led and dedicated vaccine prescriber.
• Opportunistic inpatient vaccination is generally accepted by patients and healthcare staff.

Clinical Implications

Healthcare providers should consider implementing dedicated vaccination roles within hospitals to enhance vaccine uptake among older adults. Additionally, integrating vaccination into the admission process can capitalize on the opportunity to reach high-risk patients effectively.

Conclusion

The study underscores the importance of innovative vaccination strategies in hospitals to improve coverage among older adults. Further research is needed to optimize these models for broader implementation.

References

1. Open Forum Infectious Diseases, 2023 -- Comparative Analysis of Immunogenicity and Safety Between Higher-Valent Pneumococcal Conjugate Vaccines and the 13-Valent Vaccine in Elderly Populations: A Systematic Review and Meta-Analysis of Randomized Trials
2. The Journal of Infectious Diseases, 2023 -- Comparative Effectiveness of High-Dose and Standard-Dose Influenza Vaccines on Hospitalization and Mortality Rates Based on Frailty Assessment: Insights from the DANFLU-1 Randomized Trial Post Hoc Analysis
3. American Journal of Epidemiology, 2023 -- Assessing the Community-Level Indirect Impact of Influenza Vaccination: A Combined Approach Utilizing Mathematical Modeling and Bias Evaluation
4. Vaccinations Among Adults Age 65 and Older: United States, 2024 - NCHS Data Briefs - NCBI Bookshelf
5. The Journal of Infectious Diseases — Immune Responses of Antineuraminidase Antibodies in Elderly Individuals Following Sequential Administration of Advanced Influenza Vaccines: A Randomized Controlled Study
6. ACIP Recommendations Summary | Influenza (Flu) | CDC
7. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices
8. Vaccinations Among Adults Age 65 and Older: United States, 2024 - NCHS Data Briefs - NCBI Bookshelf